The appointment of Scott Gottlieb as FDA Commissioner brought increased optimism toward the potential benefits of adaptive trials1. Traditionally associated with more efficient trials and better prospects for patients while maintaining statistical rigor, a more holistic approach to the role of adaptive trials within the industry is making room for a transformative, arguably revolutionary, change to drug development for human impact.

Join for free to read